New survey finds rising out-of-pocket costs and affordability are primary barriers to GLP-1 access
A new nationwide Pulse Survey conducted by Navitus Health Solutions shows that nearly seven in ten Americans who have used GLP-1 medications reported that cost played a role in their decision to start or continue treatment. The survey, which included 2,000 respondents who have taken GLP-1s within the past two years, examined the use of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound, which are prescribed for Type 2 diabetes management and chronic weight management.
Health Technology Insights: Ambience Healthcare Teams With MultiCare on AI Platform Rollout
Sharon Faust, Chief Pharmacy Officer at Navitus Health Solutions, said that while GLP-1 medications provide significant health benefits, the survey underscores ongoing concerns about affordability and access. She noted that patients and health plan sponsors face difficult tradeoffs, and the rising demand for these medications will require strategies that ensure eligible patients can access treatment without creating unsustainable financial strain on the healthcare system.
The survey found that out-of-pocket costs are substantial for many users. Approximately 24 percent reported paying more than $250 per prescription, with nearly eight percent paying $500 or more. Individuals taking GLP-1s for weight management were almost twice as likely to pay $250 or more per fill compared with those using the medications for diabetes. In addition, 44 percent said their costs were higher than expected, 60 percent knew someone who wanted the medication but could not afford it, and among those who stopped therapy, cost was cited as the leading reason, surpassing side effects or reaching their weight goal.
Health Technology Insights: Integrity Health Cuts Costs 16 Percentage Using Lightbeam Health Platform
In response to these challenges, some patients explored alternative programs to reduce costs. Nearly 40 percent used manufacturer coupons or discount programs, and more than 83 percent believed people turn to direct-to-consumer GLP-1 programs because conventional healthcare access is either difficult or too costly. Despite these alternatives, respondents expressed safety concerns about compounded or non-FDA-approved products, with nearly 60 percent aware of potential risks and more than 86 percent willing to pay more for FDA-approved medications.
The survey also indicates broad public support for managing access to GLP-1s responsibly. Over 70 percent of participants favored policies such as prior authorization, BMI thresholds, or participation in wellness programs to ensure coverage for these drugs. Faust emphasized that addressing affordability is not simply about limiting access but about creating strategies that balance clinical appropriateness with financial sustainability. She urged collaboration among employers, health plans, and manufacturers to manage costs while maintaining patient access to necessary medications.
Health Technology Insights: Lōkahi Therapeutics Welcomes UGA Fellows to ai² Futures Lab
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
